Phenotypic, antifungal susceptibility, and molecular characterization of an Actinomucor elegans clinical isolate: first characterized record in Chile
Frontiers in Fungal Biology · 03.11.2026 · 7
DOI: 10.3389/ffunb.2026.1987730 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Fungal Biology, online erschienen am 03.11.2026. Verfasst von Eduardo Alvarez-Duarte und 2 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology and Mycology Program, Mycology Laboratory, Biomedical Sciences Institute, University of Chile, Santiago, Chile. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Invasive fungal infections (IFIs), particularly mucormycosis, represent life-threatening complications in severely immunocompromised patients. Early species-level identification and characterization of unusual opportunistic pathogens are essential for expanding epidemiological knowledge and guiding targeted antifungal management.
Methods
We performed a polyphasic characterization combining histopathology, micromorphological evaluation, internal transcribed spacer (ITS) rDNA sequencing, phylogenetic analysis, and broth microdilution antifungal susceptibility testing of a clinical isolate of Actinomucor elegans (ChFC 20) recovered from a rhinosinusal tissue biopsy of an immunocompromised pediatric oncology patient in Chile.
Results
Histopathological examination of tissue biopsy sections revealed broad, pauciseptate, ribbon-like hyphae demonstrating direct tissue invasion. The isolate grew rapidly on potato dextrose agar, producing characteristic cottony, whitish-yellow colonies with verticillate sporangiophores and non-apophysate sporangia. ITS sequencing confirmed species-level identification as Actinomucor elegans with 99% identity. In vitro susceptibility testing demonstrated low minimum inhibitory concentrations (MICs) for amphotericin B (1 µg/mL), itraconazole (1 µg/mL), isavuconazole (0.5 µg/mL), and posaconazole (0.5 µg/mL). Targeted therapy with liposomal amphotericin B combined with surgical debridement resulted in complete clinical clearance.
Conclusion
This study provides the first comprehensive phenotypic, antifungal susceptibility, and molecular characterization of an invasive Actinomucor elegans clinical isolate from Chile, underscoring the critical role of integrating histopathology with molecular phylogenetics in resolving rare mucoralean pathogens.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Microbiology and Mycology Program, Mycology Laboratory, Biomedical Sciences Institute, University of Chile, Santiago, Chile.
- Mycology Laboratory, Biomedical Department, Public Health Institute of Chile, Santiago, Chile.
Zitieren
APA
Alvarez-Duarte, E., Lara, C., & Salas-Cifuentes, V. (2026). Phenotypic, antifungal susceptibility, and molecular characterization of an Actinomucor elegans clinical isolate: first characterized record in Chile. Frontiers in Fungal Biology, 7. https://doi.org/10.3389/ffunb.2026.1987730
Vancouver
Alvarez-Duarte E, Lara C, Salas-Cifuentes V. Phenotypic, antifungal susceptibility, and molecular characterization of an Actinomucor elegans clinical isolate: first characterized record in Chile. Frontiers in Fungal Biology. 2026;7. doi:10.3389/ffunb.2026.1987730
BibTeX
@article{AlvarezDuarte2026,
author = {Alvarez-Duarte, Eduardo and Lara, Camila and Salas-Cifuentes, Valentina},
title = {Phenotypic, antifungal susceptibility, and molecular characterization of an Actinomucor elegans clinical isolate: first characterized record in Chile},
journal = {Frontiers in Fungal Biology},
year = {2026},
volume = {7},
doi = {10.3389/ffunb.2026.1987730}
}
EUVIMED